Español

Educational article

Semaglutide and cardiovascular risk: what SELECT found

Endomédicos

Endomédicos medical profile

Published 3 min read

Educational content. It does not replace an individual medical assessment and should not be used for self-medication.

Leer este artículo en español
A clinician and patient review a chart.
Who took part in SELECT and why formulation and baseline risk matter.

Who the trial studied

SELECT enrolled adults with overweight or obesity and established cardiovascular disease, without diabetes. It compared injectable semaglutide with placebo alongside usual care.

What the study observed

The semaglutide group had fewer events in the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke. Baseline risk matters when interpreting the result.

What to ask at a visit

Ask whether your situation resembles the study population and what goal treatment would serve. The findings apply to the formulation studied. Ask for separate evidence about tablets or other medicines.

When to seek medical care

If symptoms persist, test results are abnormal, or you have questions about medication, arrange an individual assessment. Do not change treatment or doses without medical guidance.

Frequently asked questions

Does the trial mean I can stop other heart medicines?

The trial added treatment to usual care. Discuss any changes with your cardiovascular team.

References

Does this topic resonate with you?

Every case is different. Book a consultation to review your history, test results and goals with a personalized plan.

Explore endocrinology care for Weight management

More articles about Weight management